Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-450 + ritonavir + ABT-072 + ribavirin
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABT-450 + ritonavir + ABT-072 + ribavirin is an investigational oral combination regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. This regimen consists of: - **ABT-450:** a potent HCV NS3/4A protease inhibitor, which blocks viral polyprotein processing and thus inhibits viral replication. - **Ritonavir:** used here as a pharmacokinetic booster to increase plasma levels of ABT-450 by inhibiting CYP3A-mediated metabolism. - **ABT-072:** a non-nucleoside HCV NS5B polymerase inhibitor (sulfonamide palm polymerase inhibitor), which interferes with HCV RNA synthesis. - **Ribavirin:** a broad-spectrum antiviral nucleoside analog that inhibits viral RNA synthesis and induces lethal mutagenesis in HCV. The combination was studied as a peginterferon-free antiviral regimen in phase 2a clinical trials of treatment-naïve, non-cirrhotic HCV genotype 1 patients and showed high rates of sustained virologic response (SVR) and favorable safety/tolerability[1][2][4][7].
- Other names
- ABT-450/r + ABT-072 + ribavirin
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)CYP3A (CYP3A family)
Beyond the preview
Go deeper on ABT-450 + ritonavir + ABT-072 + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-450 + ritonavir + ABT-072 + ribavirin.